Progentec Diagnostics
Progentec is dedicated to providing comprehensive solutions for autoimmune disease management by combining proprietary blood biomarkers with high sensitivity and specificity, along with continuous remote digital monitoring. Their mission is to revolutionize the care of autoimmune patients through innovative proteomics and digital health tools, aiming to benefit millions worldwide.
Industries
Nr. of Employees
small (1-50)
Progentec Diagnostics
Patents
Biomarkers for a systemic lupus erythematosus (SLE) disease activity immune index that characterizes disease activity
US-12510539-B2
View DetailsSystems and methods for managing autoimmune conditions, disorders and diseases
US-11257579-B2
View Details
Biomarkers for a systemic lupus erythematosus (SLE) disease activity immune index that characterizes disease activity
US-12510539-B2
View DetailsSystems and methods for managing autoimmune conditions, disorders and diseases
US-11257579-B2
View DetailsProducts
Blood-based flare risk index test
A laboratory blood test that generates an index estimating the near-term risk of disease flare in autoimmune disease patients.
Blood-based disease activity index test
A laboratory blood test that quantifies molecular signals associated with current disease activity in autoimmune conditions.
Digital disease management platform for autoimmune patients
A patient-facing digital platform that combines validated blood biomarkers with remote continuous monitoring and mobile tools to support long-term disease management.
21 CFR Part 11–compliant remote clinical research platform
A software platform enabling fully remote clinical studies with compliant eConsent, secure data capture, and participant task management.
Patient community and engagement tools
A suite of patient engagement offerings including a community website, mobile app, newsletter, Q&A forum, and patient advisory council.
aiSLE® DX
A disease activity product candidate for systemic lupus erythematosus powered by LiquidDiseaseActivity™ Technology.
Blood-based flare risk index test
A laboratory blood test that generates an index estimating the near-term risk of disease flare in autoimmune disease patients.
Blood-based disease activity index test
A laboratory blood test that quantifies molecular signals associated with current disease activity in autoimmune conditions.
Digital disease management platform for autoimmune patients
A patient-facing digital platform that combines validated blood biomarkers with remote continuous monitoring and mobile tools to support long-term disease management.
21 CFR Part 11–compliant remote clinical research platform
A software platform enabling fully remote clinical studies with compliant eConsent, secure data capture, and participant task management.
Patient community and engagement tools
A suite of patient engagement offerings including a community website, mobile app, newsletter, Q&A forum, and patient advisory council.
aiSLE® DX
A disease activity product candidate for systemic lupus erythematosus powered by LiquidDiseaseActivity™ Technology.
Services
Laboratory-based testing and reporting of blood biomarkers used to assess disease activity and flare risk in autoimmune conditions.
Design and operational support for fully remote clinical studies, including eConsent, participant assessments, wearable integration, and study data management.
Development and provision of patient-facing mobile applications, web portals, newsletters, and moderated community forums for disease tracking and education.
Research and development services focused on discovery, analytical validation, and translation of protein biomarkers into clinical assays.
Laboratory-based testing and reporting of blood biomarkers used to assess disease activity and flare risk in autoimmune conditions.
Design and operational support for fully remote clinical studies, including eConsent, participant assessments, wearable integration, and study data management.
Development and provision of patient-facing mobile applications, web portals, newsletters, and moderated community forums for disease tracking and education.
Research and development services focused on discovery, analytical validation, and translation of protein biomarkers into clinical assays.
Expertise Areas
- Decentralized clinical trial management
- Proteomics and blood-based biomarker development
- Digital health and remote patient monitoring
- Digital biomarker derivation and validation
Key Technologies
- Proteomics
- Digital biomarker development
- Mobile health applications (iOS/Android)
- Wearable sensor data integration
News & Updates
aiSLE® DX Flare Risk Index and aiSLE® DX Disease Activity Index tests are available through Mayo Clinic Laboratories effective April 25
A remote clinical study exploring digital biomarkers for lupus using patient-reported outcomes and biometric data.
A webinar featuring Progentec's leadership discussing the development of the aiSLE™ DX Flare Risk Index.
aiSLE® DX Flare Risk Index and aiSLE® DX Disease Activity Index tests are available through Mayo Clinic Laboratories effective April 25
A remote clinical study exploring digital biomarkers for lupus using patient-reported outcomes and biometric data.
A webinar featuring Progentec's leadership discussing the development of the aiSLE™ DX Flare Risk Index.